Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic
Rhinoconjunctivitis
Asthma, Allergic

Interventions

BIOLOGICAL: 10,000 MM09
BIOLOGICAL: 30,000 MM09
BIOLOGICAL: Placebo subcutaneous

Sponsor

Inmunotek S.L.

Collaborators

[object Object]